MDL Track
MDL 3026
N.D. Ill.
Abbott preterm infant nutrition products liability
779 pending
Pharmaceutical · claims that premature infant formula increased necrotizing enterocolitis risk
Defendant
Abbott Laboratories
MDL / Track
MDL 3026
N.D. Ill.
Judge
Judge Rebecca R. Pallmeyer
Plaintiffs
~797 pending (779 per JPML March 2, 2026 report, plus ~18 new filings tracked since)
Bellwether / Trial
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
The NEC infant formula litigation has no global settlement as of mid-2026, with state court juries awarding over $555 million in verdicts against Abbott and Mead Johnson while federal MDL 3026 (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation) before Judge Rebecca R. Pallmeyer in the Northern District of Illinois consolidates approximately 797 cases. The first three federal bellwether cases were dismissed on summary judgment in 2025-2026 after Judge Pallmeyer found plaintiffs failed to establish feasible alternatives existed at scale, though a Missouri appeals court upheld the full $495 million Gill v. Abbott verdict and a Chicago jury awarded $70 million to four families in April 2026. Abbott settled one bellwether case mid-trial in March 2026 with undisclosed terms.
Causation Theory
Plaintiffs allege cow's milk-based premature infant formulas cause necrotizing enterocolitis through a biological mechanism where complex proteins and fats overwhelm the premature gut, feed harmful bacteria, and activate inflammatory pathways destroying intestinal tissue. A 2024 Cochrane meta-analysis found 67% increased NEC risk in randomized trials for formula-fed premature infants, with cohort studies showing 226% increased risk and case-control studies showing 135% increased odds. An NIH-funded JAMA study of 483 extremely preterm infants found donor human milk reduced NEC incidence to 4.2% versus 9% for formula-fed infants. The FDA, CDC, and NIH issued an October 2024 joint statement concluding there is 'no conclusive evidence that preterm infant formula causes NEC,' framing the elevated risk as absence of human milk's protective factors rather than formula toxicity.
Case Management Orders
Litigation status
MDL 3026 (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation) sits before Judge Rebecca R. Pallmeyer in the Northern District of Illinois. The first federal bellwether to reach a jury, Inman v. Mead Johnson (Enfamil), is scheduled for July 6, 2026, following three consecutive Abbott summary judgment dismissals. Second-wave Similac bellwethers are set for August 2026, November 2026, and February 2027.
MDL Track
MDL 3026
N.D. Ill.
Abbott preterm infant nutrition products liability
779 pending
State Court Activity
Thousands consolidated in Madison County, Ill.; active trials in Cook County, Ill. and St. Louis, Mo.; California filings increasing
MDL 3026 Leadership
Plaintiff Leadership
Plaintiffs' Steering Committee
Plaintiffs' Co-Lead Counsel
C. Andrew Childers
Levin, Papantonio, Proctor, Buchanan, O'Brien, Barr & Mougey, P.A.
achilders@levinlaw.com(850) 435-7000Defense Leadership
Defense Co-Liaison Counsel
Defense Lead Counsel
Geographic exposure
Approximately 377,000 annual premature births in U.S.; NEC affects 7-10% of very low birth weight preterm infants. Nationwide exposure through NICU-administered cow's milk-based formulas (Similac, Enfamil, fortifiers) across all 50 states. ~1,000 total cases pending: 782 in federal MDL 3026, hundreds more in state courts. No global settlement; individual verdicts ranging $60M-$495M.
MDL 3026 hub: 782 federal cases pending before Chief Judge Rebecca R. Pallmeyer as of April 2026. State-level consolidation: 20+ cases before Judge Dennis Ruth in Madison County; Abbott seeking transfer to Cook or Lake County under forum non conveniens. April 2026 Cook County verdict: $70 million to four families ($7M-$16M per family).
$495 million verdict upheld on appeal July 2024 (Gill v. Abbott) — $95M compensatory, $400M punitive; Missouri Supreme Court review pending. October 2024 defense verdict overturned. Five-year statute of limitations applies.
March 2024 verdict: $60 million wrongful death against Mead Johnson (Enfamil). First major plaintiff verdict in litigation.
Emerging battleground; individual cases proceeding without consolidation. Plaintiffs frequently suing hospitals alongside Abbott and Mead Johnson. First Philadelphia trial expected spring 2026.
Kansas City family filed 2026; infant born 27 weeks, under 2 lbs, fed cow's milk formula in New Jersey NICU. Remains in state court due to in-state defendants; not absorbed into federal MDL.
Family filed MDL 3026 2024; infant born 27 weeks, 2+ lbs, developed NEC after Similac feeding in NICU.
Winchester Hospital identified as site of premature birth in active NEC litigation involving Similac products.
One-year statute of limitations (shortest in nation); discovery rule may extend filing deadlines.
One-year statute of limitations; discovery rule may extend filing deadlines.
Six-year statute of limitations (longest in nation).
Key defendants
Abbott Laboratories
Role: Manufacturer
Lost $495M Missouri state verdict but won third consecutive MDL bellwether trial October 2025. Daubert motions to exclude plaintiffs' experts denied by Judge Pallmeyer in MDL 3026. Illinois Appellate Court rejected venue transfer bids June 2025, keeping cases in Madison County.
Mead Johnson & Company, LLC
Role: Manufacturer
Reckitt subsidiary facing parallel exposure. Bellwether sequence set with Inman v. Mead Johnson first. No reported trial wins yet; settlement posture unclear.
St. Louis Children's Hospital
Role: Institutional Defendant
Named in Whitfield v. St. Louis Children's Hospital, rare provider-targeted case tried in Missouri. Defense verdict returned—suggesting hospitals may resist settlement unless specific feeding-protocol failures alleged.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Abbott Laboratories | Manufacturer | Lost $495M Missouri state verdict but won third consecutive MDL bellwether trial October 2025. Daubert motions to exclude plaintiffs' experts denied by Judge Pallmeyer in MDL 3026. Illinois Appellate Court rejected venue transfer bids June 2025, keeping cases in Madison County. |
| Mead Johnson & Company, LLC | Manufacturer | Reckitt subsidiary facing parallel exposure. Bellwether sequence set with Inman v. Mead Johnson first. No reported trial wins yet; settlement posture unclear. |
| St. Louis Children's Hospital | Institutional Defendant | Named in Whitfield v. St. Louis Children's Hospital, rare provider-targeted case tried in Missouri. Defense verdict returned—suggesting hospitals may resist settlement unless specific feeding-protocol failures alleged. |
Timeline
MDL 3026 Established in N.D. Illinois
Judicial Panel on Multidistrict Litigation consolidates federal NEC baby formula cases as MDL 3026, In re: Preterm Infant Nutrition Products Liability Litigation, before Chief Judge Rebecca R. Pallmeyer.
First Major Plaintiff Verdict: $60M Against Mead Johnson
St. Clair County, Illinois jury awards $60 million in Watson v. Mead Johnson, first substantial NEC verdict. Illinois Fifth District Appellate Court reverses verdict June 2026, orders new trial.
$495M Missouri Verdict Against Abbott
St. Louis Circuit Court jury awards $495 million ($95M compensatory, $400M punitive) in Gill v. Abbott Laboratories. Missouri Court of Appeals upholds full verdict; Abbott seeks review in Missouri Supreme Court.
Only Defense Verdict Overturned for Misconduct
Missouri judge vacates October 2024 defense verdict, orders new trial, sanctions defense counsel for bad faith violations and misleading jurors.
Third Federal Bellwether Dismissed on Summary Judgment
Judge Pallmeyer grants Abbott summary judgment in third consecutive MDL bellwether, excluding plaintiff causation expert under Daubert. MDL 3026.
$70M Chicago Verdict for Four Families Against Abbott
Cook County jury awards $70 million ($53M compensatory, $17M punitive) to four families in consolidated trial involving Similac Special Care 24. Abbott announces intent to appeal.
First Mead Johnson Bellwether Clears Summary Judgment
Judge Pallmeyer denies Mead Johnson's summary judgment motion in Inman v. Mead Johnson, allowing first Enfamil case in MDL to proceed. Case No. 1:22-cv-0373.
Watson Verdict Reversed on Appeal
Illinois Fifth District Appellate Court reverses $60 million Watson verdict against Mead Johnson, orders new trial, citing improper admission of financial evidence regarding company revenues and executive compensation.
First Federal MDL Jury Trial Begins
Inman v. Mead Johnson, first NEC case to reach federal MDL jury, begins trial in N.D. Illinois. First Enfamil bellwether; no verdict reported as of mid-July 2026.
Statute of limitations
Discovery rule applicability varies by state and materially affects NEC cases where diagnosis may post-date NICU discharge by months or years. Source [2] and [3] emphasize discovery rule may extend filing deadlines when harm was not immediately discoverable. Source [4] notes Kentucky and Louisiana have 1-year deadlines (shortest); Maine and North Dakota 6 years; Missouri 5 years. No global tolling agreement confirmed in sources; individual tolling agreements may exist. MDL 3026 centralized in N.D. Ill. per JPML order January 2024.
Illinois
2 years from discovery
Rule: 735 ILCS 5/13-202(a) (product liability); discovery rule applies per standard Illinois tort accrual
Discovery: Accrues when plaintiff knew or reasonably should have known of injury and its causal connection to formula
Home to Abbott Laboratories and Mead Johnson headquarters; venue of choice for many filings. Source [2] confirms 2-year deadline with discovery rule extension. Minority tolling: 735 ILCS 5/13-211 suspends until age 18, then 2 years to file
Florida
2 years from injury
Rule: Fla. Stat. § 95.11(3)(a) (product liability)
Discovery: Limited; state may allow exceptions under certain circumstances per source [1]
Source [1] confirms 2-year deadline per § 95.11. Minority tolling: § 95.051 gives minors additional time. Source [1] notes exceptions for parents under certain circumstances—speaking to lawyer advised
California
2 years from injury
Rule: Cal. Code Civ. Proc. § 335.1
Source [4] confirms 2-year deadline. No minority tolling for product liability; parents must file derivative claims within 2 years
Texas
2 years from injury
Rule: Tex. Civ. Prac. & Rem. Code § 16.003(a)
Source [4] confirms 2-year deadline among most states. Minority tolling typically until age 18, then 2 years
New York
3 years from injury
Rule: N.Y. C.P.L.R. § 214
Source [4] confirms 3-year deadline. Infant tolling: § 208 suspends until age 18, then 3 years
Pennsylvania
2 years from injury
Rule: 42 Pa. Cons. Stat. § 5524
Source [4] confirms 2-year deadline. Minority tolling: § 5533 tolls until age 18, then 2 years
⚠Michigan
3 years from injury
Rule: Mich. Comp. Laws § 600.5805
Source [4] confirms 3-year deadline. Minority tolling: § 600.5851 tolls until age 18, then 1 year—short post-minority window creates intake urgency
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| Illinois | 2 years from discovery | 735 ILCS 5/13-202(a) (product liability); discovery rule applies per standard Illinois tort accrual | Accrues when plaintiff knew or reasonably should have known of injury and its causal connection to formula | Home to Abbott Laboratories and Mead Johnson headquarters; venue of choice for many filings. Source [2] confirms 2-year deadline with discovery rule extension. Minority tolling: 735 ILCS 5/13-211 suspends until age 18, then 2 years to file |
| Florida | 2 years from injury | Fla. Stat. § 95.11(3)(a) (product liability) | Limited; state may allow exceptions under certain circumstances per source [1] | Source [1] confirms 2-year deadline per § 95.11. Minority tolling: § 95.051 gives minors additional time. Source [1] notes exceptions for parents under certain circumstances—speaking to lawyer advised |
| California | 2 years from injury | Cal. Code Civ. Proc. § 335.1 | — | Source [4] confirms 2-year deadline. No minority tolling for product liability; parents must file derivative claims within 2 years |
| Texas | 2 years from injury | Tex. Civ. Prac. & Rem. Code § 16.003(a) | — | Source [4] confirms 2-year deadline among most states. Minority tolling typically until age 18, then 2 years |
| New York | 3 years from injury | N.Y. C.P.L.R. § 214 | — | Source [4] confirms 3-year deadline. Infant tolling: § 208 suspends until age 18, then 3 years |
| Pennsylvania | 2 years from injury | 42 Pa. Cons. Stat. § 5524 | — | Source [4] confirms 2-year deadline. Minority tolling: § 5533 tolls until age 18, then 2 years |
| ⚠Michigan | 3 years from injury | Mich. Comp. Laws § 600.5805 | — | Source [4] confirms 3-year deadline. Minority tolling: § 600.5851 tolls until age 18, then 1 year—short post-minority window creates intake urgency |
Live intelligence
AI litigation brief
NEC Baby Formula remains active mdl with 79 current signals in the accepted feed.
Overview
MDL 3026 (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation) sits before Judge Rebecca R. Pallmeyer in the Northern District of Illinois. The first federal bellwether to reach a jury, Inman v. Mead Johnson (Enfamil), is scheduled for July 6, 2026, following three consecutive Abbott summary judgment dismissals. Second-wave Similac bellwethers are set for August 2026, November 2026, and February 2027.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3026, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 3026 should stay on the lead docket watch because it is the primary consolidation vehicle for NEC Formula.
Generated Aug 12, 2026, 3:00 AM UTC
79 events detected
Google News (33)
JURISDICTION—BABY PRODUCTS—7th Cir.: Infant formula makers fail to establish fraudulent joinder based on parents’ litigation conduct - VitalLaw.com
Abbott Notches Appellate Win in Bellwether Infant Formula Case - Bloomberg Law News
Why Neonatal Health Advocates Are Raising the Alarm on Formula - South Florida Caribbean News
‘Live insect’ in baby formula: Court drops case against Ex-Mead Johnson India MD - The Indian Express
Infant Formula Manufacturers Decide Whether to Inform FDA About Possible Harm - Truthout
What to Know About the First Federal NEC Baby Formula Lawsuit - The Legal Examiner
Infant Formula Makers Were Required to Tell the FDA When Babies Died — Records Show They Never Did - inkl
The Fox Has Been Guarding the Henhouse for Years: Infant Formula Makers Decide for Themselves Whether Baby Deaths Get Reported to the FDA - Marler Blog
Mead Johnson Wins Defense Verdict in Latest NEC-Related Infant Formula Trial - Law.com
A Mom Said Infant Formula Killed Her Baby. The Manufacturer Closed the File. - KFF Health News
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula - Reuters
Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe - Yahoo Finance
Abbott Sheds Criminal Cloud, But Civil Storm Looms Large - Kavout | AI
DOJ ends Abbott baby formula criminal probe, opts for civil action - MSN
Exclusive | The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case. - WSJ
Counselor to Counselor: An Open Letter to Kyle Diamantas on Infant Formula - Marler Blog
Litigators of the (Past) Week: Reversing a $60M Loss in Bellwether Baby Formula Case for Mead Johnson - Law.com
Bucks County couple files lawsuit against formula company after baby hospitalized with infant botulism - PhillyVoice
Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court - Reuters
Lawsuit Accuses Nara Organics of Selling Whole-Milk Infant Formula that Carried Botulism Spores - Marler Blog
Mead Johnson Lawsuit 2026: Payouts and Updates - LawFold.com
Infant-formula damages verdict against Mead Johnson overturned - Global Food Industry News
Mead Johnson wins new trial as court reverses $60 million preterm formula verdict - Reuters
Appeals court dumps $60M baby formula NEC verdict vs Mead Johnson - www.cities929.com
Mead Johnson Wins New Trial Over $60M NEC Formula Verdict - Law360
Reckitt’s Mead Johnson Granted New Trial Over Baby Formula Death - Bloomberg Law News
Similac baby formula maker sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com
NEC Baby Formula Lawsuit 2026 Update: What Families Need to Know - Edgar Snyder & Associates
Preterm Infant Formula Argument Focuses on Feeding Alternatives - Bloomberg Law News
Nestle and Danone face fresh scrutiny over infant formula recalls - Reuters
7th Circ. Weighs If Abbott Warning Would Change NEC Care - Law360
Judge sets up high stakes baby formula NEC trial vs Mead Johnson - The Black Chronicle
Abbott Securities Lawsuit Deepens Infant Formula Risks For Shareholders - Sahm
Pediatrics international : official journal of the Japan Pediatric Society • Oshiro M • PMID 41988811 • Journal Article.
JPEN. Journal of parenteral and enteral nutrition • Pai N • PMID 42547409 • Journal Article.
Journal of neonatal-perinatal medicine • Patil MS • PMID 42527892 • Journal Article.
Clinical pediatrics • Getaneh FB • PMID 42522279 • Journal Article.
Frontiers in immunology • Tan XD • PMID 42528654 • Journal Article.
No recent FDA signals. Monitoring is active — this section updates automatically.
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket filed in JPML: The plaintiffs are suing the manufacturers of 'Similac' and 'Enfamil' cow's milk-based infant feeding products, alleging that these products caused a severe gastrointestinal condition called necrotizing enterocolitis (NEC) in the infant plaintiff L.K. The lawsuit claims that there were safer human m
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT filed by ZACHARY HERNANDEZ; Jury Demand. Filing fee $ 405, receipt number AILNDC-25507615. (Attachments: # 1 Civil Cover Sheet)(Gancedo, Amanda) (Entered: 08/10/2026)
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT filed by Darius Robinson; Jury Demand. Filing fee $ 405, receipt number AILNDC-25501362.(Wexler, Noah) (Entered: 08/07/2026)
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT filed by Tiffany Heck ; Jury Demand. Filing fee $ 405, receipt number AILNDC-25489712.(Wexler, Noah) (Entered: 08/05/2026)
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT filed by Camren Diaz; Jury Demand. Filing fee $ 405, receipt number AILNDC-25487933. (Attachments: # 1 Civil Cover Sheet, # 2 Notice of Filing Cover Sheet)(Poirot, Joseph) (Entered: 08/05/2026)
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT Receipt No: ACACDC-42774739 - Fee: $405, filed by Plaintiffs Christina Barocio, Bryan Barocio. (Attorney Fabrice N. Vincent added to party Bryan Barocio(pty:pla), Attorney Fabrice N. Vincent added to party Christina Barocio(pty:pla))(Vincent, Fabrice) [Transferred from California Central o
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT filed by Desiree McGregor; Jury Demand. Filing fee $ 405, receipt number AILNDC-25482563.(Saucier, Mackenzi) (Entered: 08/04/2026)
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from MAD: COMPLAINT AND JURY DEMAND against Abbott Laboratories, Inc. Filing fee: $ 405, receipt number AMADC-11925944 (Fee Status: Filing Fee paid), filed by Rebecca Kimball. (Attachments: # 1 Civil Cover Sheet, # 2 Category Form)(Lamkin, Julie) Modified on 7/30/2026: Removed duplicate text. Complaint has be
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT filed by Chrisjahnay Gorham, Shareeka Lewis; Jury Demand. Filing fee $ 405, receipt number AILNDC-25454544.(Douglas, James) (Entered: 07/29/2026)
Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation
PACER docket entry from ILND: COMPLAINT filed by Reatha Whiteman; Jury Demand. Filing fee $ 405, receipt number AILNDC-25433513. (Attachments: # 1 Disclosure Statement)(Wallace, Edward) (Entered: 07/24/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
82Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Aug 12, 2026, 3:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
79
events detected
AI Brief
NEC Baby Formula remains active mdl with 79 current signals in the accepted feed.
Overview
MDL 3026 (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation) sits before Judge Rebecca R. Pallmeyer in the Northern District of Illinois. The first federal bellwether to reach a jury, Inman v. Mead Johnson (Enfamil), is scheduled for July 6, 2026, following three consecutive Abbott summary judgment dismissals. Second-wave Similac bellwethers are set for August 2026, November 2026, and February 2027.
Key developments
PACER court filing on Dec 31: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation. ‖ VitalLaw.com news on Aug 4: JURISDICTION—BABY PRODUCTS—7th Cir.: Infant formula makers fail to establish fraudulent joinder based on parents’ litigation conduct - VitalLaw.com. ‖ PubMed research on Dec 1: Antenatal Bartter Syndrome Type 4a: Ibuprofen Treatment for a Challenging Case of Very Low Birth Weight Infant..
Generated Aug 12, 2026, 3:00 AM UTC
Tracked MDLs
MDL 3026
N.D. Ill.
Abbott preterm infant nutrition products liability